Company intelligence / Profile preview
Koronis Pharmaceuticals
Seattle, Washington, United Stateskoronispharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Koronis Pharmaceuticals developed antiviral therapeutics using a novel mechanism called Viral Decay Acceleration. Its lead candidate, KP‑1461, was a small molecule targeting HIV by accelerating viral mutation rates to cause collapse of the virus population. Clinical trials included Phase 1 and Phase 2 studies in treatment-experienced HIV patients but were ultimately terminated/discontinued without successful efficacy results. The company also had preclinical programs for hepatitis C and RSV. There is no evidence of ongoing clinical development or commercial products.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships reported.
Beyond the preview
Go deeper on Koronis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Koronis Pharmaceuticals.